Where does NGM Biopharmaceuticals, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), NGM Biopharmaceuticals, Inc. ranks #4,902 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does NGM Biopharmaceuticals, Inc. hold?

NGM Biopharmaceuticals, Inc. holds 71 US utility patents granted between 2015 and 2025, spanning 7 technology areas.

What is NGM Biopharmaceuticals, Inc.'s Innovation Score?

NGM Biopharmaceuticals, Inc. has an Innovation Score of 43.1 out of 100 (top 29% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does NGM Biopharmaceuticals, Inc. focus on?

NGM Biopharmaceuticals, Inc.'s top technology area is C07K (Peptides) with 68 patents, ranking #120 of 3,615 assignees active in that subclass. Grants appear in 7 CPC subclasses total.

Is NGM Biopharmaceuticals, Inc.'s patent grant rate increasing or decreasing?

NGM Biopharmaceuticals, Inc.'s recent grant velocity is +3% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for NGM Biopharmaceuticals, Inc.'s patents?

NGM Biopharmaceuticals, Inc.'s patents average 40.5 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the NGM Biopharmaceuticals, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

NGM Biopharmaceuticals, Inc.

USPTO PatentsView assignee record - 71 granted patents across 7 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, NGM ranks #4,902 of 49,997 tracked US assignees by granted-patent volume, with 71 patents across 7 technology areas.

#4,902
of 49,997 US assignees by volume: Top 29%
by Innovation Score (43.1/100): 40.5
avg claims per patent: +3%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R4902 · US Corporation #4,902 · 71 grants

GRANTS-SMALL · TOP-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · VEL-FLAT · BOOK-FULL

GRANTS-SMALL 71 grants
TOP-DECILE #4,902/49,997
PHOTO-FINISH Matthews International
CPC-NARROW C07K · 7 areas
INNOV-PAR 43.1/100
CLAIMS-DENSE 40.5 claims/avg
TYPE-USCORP US Corporation
VEL-FLAT +3% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Matthews International Corporation (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How NGM’s 43.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 14.8 pts (34%) Velocity 4.0 pts (9%) Breadth 9.4 pts (22%) Claim depth 15.0 pts (35%)

Qualcomm Incorporated · highest

85
Apollo Tyres Global… · near

43
Atrium Medical · near

43
Choon's Design · near

43
Dowa Metaltech · near

43
NGM Biopharmaceuticals · this assignee

43
3D Lighting… · lowest

7

What this shows NGM's Innovation Score is 43.1/100 (top 29% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for NGM?

Each dot is one of NGM’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). NGM’s own 40.5 claims/patent is ABOVE the 14.8 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

NGM vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where NGM's grants concentrate

NGM Biopharmaceuticals, Inc. is a focused PatentsView assignee: 7 CPC subclasses with 95.8% of grants classified under C07K (Peptides). Peak complete grant year is 2018 (11 grants) versus a trough of 2 in 2016. By volume, NGM sits between Matthews International Corporation and PME IP PTY Ltd.

NGM's three-year grant acceleration

From 2019–2021 to 2022–2024, NGM Biopharmaceuticals, Inc. moved from 27 to 16 grants (0.59x the prior three-year total, a multiple, not a CAGR). See the growth leaderboard.

Matthews Internat…

71
Mcalister

71
National Universi…

71
National Universi…

71
Nuvera Fuel Cells

71
Ohio State Univer…

71
Omeros

71
PME IP PTY

71
NGM Biopharmaceut… ◀

71

What this shows NGM holds 71 patents at rank #4,902, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near NGM

By rank, the assignees closest to #4,902 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in NGM's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for NGM, neither rank-band nor same-CPC leaders (those blocks stay above). In C07K (Peptides), NGM ranks #120 of 3,615 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (43 here).

Dowa Metaltech Co., Ltd. 43 Atrium Medical Corporation 43 Choon's Design LLC 43 Apollo Tyres Global R&D B.V. 43

Similar claim depth

Nearest assignees by average claims per patent (40.5 here).

Vicor Corporation 39.7 avg CertusView Technologies, LLC 39.0 avg Berkshire Grey, Inc. 38.9 avg Kemet Electronics Corporation 37.8 avg

NGM's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

43 Top 29% higher than 71% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

NGM Biopharmaceuticals, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	3	4.2%
2016	2	2.8%
2017	8	11.3%
2018	11	15.5%
2019	9	12.7%
2020	10	14.1%
2021	8	11.3%
2022	4	5.6%
2023	10	14.1%
2024	2	2.8%
2025partial year	4	5.6%

Which technologies does NGM Biopharmaceuticals, Inc. patent most?

C07K - Peptides 68

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 67

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 49

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 31

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 3

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 3

A01K - Animal HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; Rearing OR Breeding Animals, NOT Otherwise Provided FOR; NEW Breeds OF Animals 1

Top 7 of 7 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

NGM Biopharmaceuticals, Inc.'s patent record in context - here's where to go next.

NGM Biopharmaceuticals, Inc.'s lead technology class is C07K (Peptides), 95.8% of its portfolio - see every assignee active in that class. Explore C07K
Ranked #4,902 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare NGM Biopharmaceuticals, Inc. against Matthews International Corporation, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 43.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.